Drugs / calcium acetate
calcium acetate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PROCALAMINE | — | 1982-05-06 | fda.gov ↗ |
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04299633 | Jun → Aug 2020 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05424263 | Sep 2022 → Jul 2025 | arterial disorder, premature aging syndrome, vascular ectasia | University of Colorado, Denver | Unknown | No outcome recorded |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT03202407 | Aug 2017 → Aug 2018 | hyperphosphatemia | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT01191255 | Oct 2010 → Jan 2013 | hyperphosphatemia, kidney failure | Keryx Biopharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00211978 | May 2005 → Jun 2006 | hyperphosphatemia, kidney failure | Nabi Biopharmaceuticals | Completed | Met primary |
| Phase 45 trials | ||||||
| Phase 4 | NCT04485039 | Jun → Dec 2022 | smallpox | SIGA Technologies | Completed | No outcome recorded |
| Phase 4 | NCT01427907 | Sep 2011 → Jul 2012 | chronic kidney disease | Fresenius Medical Care North America | Completed | No outcome recorded |
| Phase 4 | NCT01135615 | Jan 2008 → Apr 2010 | — | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00211939 | Jan 2005 → Dec 2006 | arteriosclerosis disorder, calcinosis, secondary hyperparathyroidism | Nabi Biopharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00486772 | — | vascular disorder | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00364000 | Jan 2012 → Jul 2015 | hyperphosphatemia | Romanian Society of Nephrology | Withdrawn | No outcome recorded Stop: Business |
| — | NCT00018135 | — | kidney failure | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 0 | NCT01991574 Comparator | Apr → Oct 2009 | chronic kidney disease | Medical Research Council | Completed | No outcome recorded |
| Phase 2/3 | NCT03824587 Background | Feb → Jul 2019 | hyperphosphatemia | Ardelyx | Completed | Met primary |
| Phase 3 | NCT02688764 Comparator | May 2016 → Feb 2019 | hyperphosphatemia | Vifor Fresenius Medical Care Renal Pharma | Terminated | Missed primary |
| Phase 3 | NCT01357317 Comparator | Jun 2011 → Oct 2013 | chronic kidney disease | Salem Veterans Affairs Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00196755 Comparator | Dec 2004 → Mar 2006 | chronic kidney disease | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01277497 Comparator | Jan 2011 → Jan 2016 | chronic kidney disease | Albany College of Pharmacy and Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01755078 Comparator | Jun 2007 → Jun 2009 | hyperphosphatemia | Chugai Pharma Taiwan | Completed | No outcome recorded |
| — | NCT02273570 Background | Mar 2015 → Dec 2016 | secondary hyperparathyroidism of renal origin | Azienda Ospedaliera Sant'Anna | Unknown | No outcome recorded |
| — | NCT00785629 Comparator | Feb 2009 → Jul 2011 | chronic kidney disease | Denver Nephrologists, P.C. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-10-26 | Lupin Limited | Lupin Launches Generic PhosLo® in the US lupin.com ↗ |
| 2012-06-06 | Perrigo Company | Perrigo Receives FDA Approval for Calcium Acetate Capsules perrigo.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcium acetate | “Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial.” PMID 29989014 ↗ Mar 201820“calcium acetate("Phoslo®"), calcium acetate/magnesium carbonate ("Osvaren®")” NCT02273570 ↗ “AC (sevelamer carbonate and/or calcium acetate)” PMID 26239948 ↗ Sep 2015 “calcium acetate” NCT03824587 ↗ “Calcium acetate” NCT01755078 ↗ |
| Known as | Acetic acid, calcium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Acetic acid, calcium salt (2:1) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Calcarea acetica | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Calcium acetate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Calcium acetate component of procalamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | COS | “The investigational compound is calcium acetate oral solution (COS) or Phoslyra.” NCT01427907 ↗ |
| Known as | E-263 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Eliphos | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Everose | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | FEMA NO. 2228 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | INS NO.263 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | INS-263 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Phos Ex | “Patients were randomly assigned in 1:1 ratio to receive sevelamer (Renagel capsule) or calcium acetate (Phos Ex tablet).” NCT01135615 ↗1“Patients were randomly assigned in 1:1 ratio to receive sevelamer (Renagel capsule) or calcium acetate (Phos Ex tablet).” NCT00486772 ↗ |
| Known as | PhosLo | “calcium acetate("Phoslo®"), calcium acetate/magnesium carbonate ("Osvaren®")” NCT02273570 ↗1“Calcium acetate (PhosLo® )” NCT00196755 ↗ |
| Known as | Phoslo gelcaps | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Known as | Phoslyra | “Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.” NCT02688764 ↗ |
| Known as | Renacet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200800 ↗ |
| Modality | Other / unclassified | “Calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification” NCT00364000 ↗ |
| Route | Oral | “Oral Solution” NCT02688764 ↗ |